SEARCH    

A Tabulated Summary of the FDG PET Literature

Contents:

References

  1. AAssar OS, Fischbein NJ, Caputo GR, et al. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors. Radiology 1999;210:177 - 181.
  2. Abdel-Nabi H, Abou-Zied MM, Doerr RJ. Preoperative evaluation of patients with suspected liver metastases with positron emission tomography with F - 18 FDG . J Nucl Med 1999;40:241P.
  3. Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998;206:755 - 760.
  4. Achten E, Santens P, Boon P, et al. Single-voxel proton MR spectroscopy and positron emission tomography for lateralization of refractory temporal lobe epilepsy. Am J Neuroradiol 1998;19:1 - 8.
  5. Acland KM, O´Doherty MJ, Russell-Jones R. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma. J Am Acad Dermatol 2000;42:606 - 611.
  6. Adams S, Baum R, Stuckensen T, Bitter K, Hör G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255 - 1260.
  7. Adler L, Crowe J, al-Kaisi N, Sunshine J. Evaluation of breast masses and axillary lymph nodes with (F-18) 2 deoxy-2-fluoro-D-glucose PET. Radiology. 1993;187:743 - 750.
  8. Adler L, Faulhaber P, Schnur K, Al-Kasai N, Shenk R. Axillary lymph node metastases: screening with (F-18)2 deoxy-2-D-glucose (FDG) PET. Radiology 1997;203:323 - 327.
  9. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid 1993;3:195 - 200.
  10. Akimura T, Yeh HS, Mantil JC, Privitera MD, Gartner M, Tomsick TA. Cerebral metabolism of the remote area after epilepsy surgery. Neurol Medico-Chirurg 1999;39:16 - 27.
  11. Al-Sugair AS, Coleman RE. Relative diagnostic efficacy of F-18 FDG PET and bone scintigraphy for detection of osseous metastases in primary or secondary lung cancer . J Nucl Med 1999;40:20P.
  12. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999;53:808 - 811.
  13. Albes JM, Lietzenmayer R, Schott U, Schülen E, Wehrmann M, Ziemer G. Improvement of non-small-cell lung cancer staging by means of positron emission tomography. Thoracic Cardiovasc Surgeon 1999;47:42 - 47.
  14. Alnafisi NS, Driedger AA, Coates G, Moote DJ, Raphael SJ. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma. J Nucl Med 2000;41:1010 - 1015.
  15. Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schäfers M, Schober O. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans. Langenbecks Arch Surg 1998;383:160 - 163.
  16. Amthauer H, Hosten N, Mueller-York A, et al. Whole body FDG-PET before laser-induced thermo-therapy (LITT) in patients with hepatic metastases of colorectal cancer . J Nucl Med 2000;41:35P.
  17. Anzai Y, Carroll WR, Quint DJ, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-(F-18)fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135 - 141.
  18. Austin JR, Wong FC, Kim EE. Positron emission tomography in the detection of residual laryngeal carcinoma. Otolaryngol Head Neck Surg 1995;113:404 - 407.
  19. Avril N, Dose J, Jänicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996;14:1848 - 1857.
  20. Avril N, Schelling M, Naehrig J, et al. Monitoring primary chemotherapy in advanced breast cancer using FDG-PET . J Nucl Med 2000;41:112P - 113P.
  21. Bachor R, Kocher F, Gropengiesser F, Reske SN, Hautmann RE. Positron emission tomography: introduction of a new imaging technique for urological tumors and initial clinical results [in German]. Urologe Ausgabe A 1995;34:138 - 142.
  22. Bachor R, Kotzerke J, Gottfried HW, Braendle E, Reske SN, Hautmann R. Positron emission tomography (PET) for diagnosis of renal cell carcinoma (RCC) [in German]. Urologe Ausgabe A 1996;35:146 - 150.
  23. Bachor R, Kotzerke J, Reske SN, Hautmann R. Lymph node staging for urinary bladder carcinoma with positron emission tomography (PET) [in German]. Urologe Ausgabe A 1999;38:46 - 50.
  24. Bader JB, Samnick S, Schaefer A, et al. Contribution of nuclear medicine to the diagnosis of recurrent brain tumors and cerebral radionecrosis [in German]. Radiologe 1998;38:924 - 929.
  25. Bader JB, Siebert S, Schaefer A, et al. Diagnostic efficiency in the detection of brain tumor recurrence at follow-up by 123I alpha-methyltyrosine-SPECT and 18FDG-PET . J Nucl Med 1997;38:239P.
  26. Baehre MH, Markert U, Meller B, et al. Oncologic information provided by immunoscintigraphy with 99mTc Fab´ fragments compared with (18F)FDG PET in colorectal cancer . J Nucl Med 2000;41:141P.
  27. Baer F, Voth E, Deutsch H. Predictive value of low-dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of left ventricular function after successful revascularization. J Am Coll Cardiol 1996;28:60 - 69.
  28. Bangerter M, Kotzerke J, Griesshammer M, Elsner K, Reske SN, Bergmann L. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncologica (Stockholm) 1999;38:799 - 804.
  29. Bangerter M, Moog F, Buchman I, et al. Whole-body 2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography FDG-PET for accurate staging of Hodgkin´s disease. Ann Oncol 1998;9:1117 - 1122.
  30. Bares R, Dohmen B, Cremerius U, Fass J, Teusch M, Buell U. Results of positron emission tomography with fluorine-18-labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma [in German]. Radiologe 1996;36:435 - 440.
  31. Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R. Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron emission tomography. Horm Metab Res. 1993;27(suppl):56 - 58.
  32. Bares R, Klever P, Hauptmann S, et al. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994;192:79 - 86.
  33. Bares R, Klever P, Hellwig D, et al. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 1993;14:596 - 601.
  34. Barrington SF, Koutroumanidis M, Agathonikou A, et al. Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies. Epilepsia 1998;39:753 - 766.
  35. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931 - 938.
  36. Baum RP, Schmuecking M, Plichta K, et al. Staging of non-small cell lung cancer (NSCLC): is PET really clinically important or just a research tool ? J Nucl Med 2000;41:293P - 294P.
  37. Beets G, Pennickx F, Schiepers C, et al. Clinical value of whole-body positron emission tomography with (18F) fluorodeoxyglucose in recurrent colorectal cancer. Br J. Surg. 1994;81:1666 - 1670.
  38. Bellon JR, Mankoff DA, Eubank WB, et al. Evaluation of the internal mammary (IM) lymph node (LN) chain by PET in locally advanced breast cancer (LABC) . J Nucl Med 2000;41:145P.
  39. Benchaou M, Lehmann W, Slosman DO, et al. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer. Acta Otolaryngol 1996;116:332 - 335.
  40. Bender H, Bangard N, Metten N, et al. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. Hybridoma 1999;18:87 - 91.
  41. Bender H, Kirst J, Palmedo H, et al. Value of 18-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res 1997;17:1687 - 1692.
  42. Berlangieri SU, Brizel DM, Scher RL, et al. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy. Head Neck 1994;16:340 - 346.
  43. Bernstein V, Jones A, Mankoff DA, Davis N. Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission tomography (FDG-PET) in medial hemisphere breast cancer . J Nucl Med 2000;41:289P.
  44. Berry WAC, Molloy PT, Alavi A, Vaughan SN. Neuroimaging in the evaluation of suspected brain tumor recurrence in the pediatric population, the critical role of fluorodeoxyglucose (18-FDG) positron emission tomography (PET) studies . J Nucl Med 1997;38:12P - 13P.
  45. Beuthien-Baumann B, Bredow J, Eckelt U, Franke WG, Hlawitschka M, Neise E. Diagnostic value of 18F-FDG PET in detecting carcinoma of the oral mucosa in comparison with MRI, CT, and ultrasound (US) . J Nucl Med. 2000;41:301P.
  46. Bischoff HG, Knopp MV, Rimac A, Manegold C, Drings P, Van Kaick G. Chemotherapy response monitoring with FDG positron emission tomography of patients with small cell lung cancer . Ann Hematol 1996;73:A99.
  47. Bleckmann C, Dose J, Bohuslavizki KH, et al. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer [see comments]. J Nucl Med 1999;40:2021 - 2024.
  48. Blessing C, Feine U, Geiger L, Carl M, Rassner G, Fierlbeck G. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma [see comments]. Arch Dermatol 1995;131:1394 - 1398.
  49. Block M, Patterson G, Sundaresan R, et al. Improvement in staging of esophageal cancer with addition of positron emission tomography. Ann Thorac Surg 1997;64:770 - 776.
  50. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery 1993;114:728 - 735.
  51. Blum DE, Ehsan T, Dungan D, Karis JP, Fisher RS. Bilateral temporal hypometabolism in epilepsy. Epilepsia 1998;39:651 - 659.
  52. Bohdiewicz PJ, Scott GC, Juni JE, et al. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations. Clin Nucl Med. 1995;20:230 - 236.
  53. Bohuslavizki KH, de Wit M, Buchert R, et al. Post-treatment 18F-FDG-PET as predictor for disease-free survival in Hodgkin´s lymphoma . J Nucl Med 2000;41:275P.
  54. Bohuslavizki KH, Klutmann S, Kröger S, et al. FDG PET detection of unknown primary tumors. J Nucl Med 2000;41:816 - 822.
  55. Bohuslavizki KH, Klutmann S, Neuber K, et al. Correlation of 18F FDG-PET and histological findings in patients with malignant melanoma . J Nucl Med 2000;41:302P.
  56. Bombardieri E, Crippa F, Agresti R, et al. FDG-PET in the assessment of axillary metastases in breast cancer. Clinical application and economic implications . J Nucl Med 1998;39:254P.
  57. Bongers V, Terhaard CJ, van Isselt JW, Hordijk GJ, van Rijk PP. Dual-head FDG-PET for the detection of recurrent laryngeal cancer compared with histopathological biopsy results and minimally 1-year clinical follow-up . J Nucl Med 2000;41:287P.
  58. Böni R, Böni RA, Steinert H, et al. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose. Br J Dermatol 1995;132:556 - 562.
  59. Both SA, Schaeffer U, Schlenger KH, et al. 18F FDG-PET in clinical assessment of primary uterine cervical carcinoma: detection and correlation with tumor oxygen partial pressure . J Nucl Med 2000;41:116P.
  60. Braams J, Pruim J, Freling N, et al. Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211 - 216.
  61. Braams JW, Pruim J, Kole AC, et al. Detection of unknown primary head and neck tumors by positron emission tomography. Int J Oral Maxillofac Surg 1997;26:112 - 115.
  62. Brandt-Mainz K, Müller SP, Görges R, Saller B, Bockisch A. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Euro J Nucl Med 2000;27:490 - 496.
  63. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J 1999;14:1376 - 1380.
  64. Bury T, Dowlati A, Paulus P, et al. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging. Eur Respir J 1996;9:410 - 414.
  65. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996;9:2560 - 2564.
  66. Cambier JPR, Flamen P, Maes A, Van Cutsem E, Lerut T, Mortelmans L. FDG-PET for staging recurrent esophageal cancer (EC) . J Nucl Med 2000;41:32P.
  67. Caputo GR, Budinger T, Price D, Schreck C, Hawkins R. Evaluation of prostate cancer using high-resolution FDG PET imaging . J Nucl Med 1997;38:128P.
  68. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998;91:3340 - 3346.
  69. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331 - 338.
  70. Chaiken L, Rege S, Hoh C, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:455 - 464.
  71. Cheon G, Chung J, So Y, et al. Diagnostic accuracy of F-18 FDG-PET in the assessment of post-therapeutic recurrence of head and neck cancer. Clin Positron Imaging 1999;2:197 - 204.
  72. Chierichetti F, Rubello D, Pedrazzoli S, et al. FDG PET role in differential diagnosis of pancreatic and peri-pancreatic masses . J Nucl Med 1997;38:51P.
  73. Chin R Jr, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995;152:2090 - 2096.
  74. Chisin R, Klein M, Freedman N, et al. PET and lymphoscintigraphic evaluation of malignant melanomas: the Hadassah Hospital experience . Clin Positron Imaging 1998;1:252.
  75. Choi JY, Lee KH, Shim YM, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000;41:808 - 815.
  76. Chugani HT, Shewmon DA, Peacock WJ, Shields WD, Mazziotta JC, Phelps ME. Surgical treatment of intractable neonatal-onset seizures: the role of positron emission tomography. Neurology 1988;38:1178 - 1188.
  77. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan [see comments]. J Nucl Med 1999;40:986 - 992.
  78. Collins BT, Gardner LJ, Verma AK, Lowe VJ, Dunphy FR, Boyd JH. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia. Acta Cytol 1998;42:1325 - 1329.
  79. Conti P, Durski J, Bacqai F, Grafton S, Singer P. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 1999;9:797 - 804.
  80. Cortes-Blanco A, Meyer PT, Martinez-Lazaro R, Desiderio LM, Molloy PT, Alavi AA. Discrepant performance of FDG-PET and magnetic resonance imaging (MRI) and spectroscopy (MRS) for the detection of brain tumor recurrence between adults and children . J Nucl Med 2000;41:225P.
  81. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403 - 1406.
  82. Cremerius U, Fabry U, Neuerburg J, Zimny M, Osieka R, Buell U. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998;19:1055 - 1063.
  83. Cremerius U, Wildberger H, Zimny M, Jaksy G, Gunther R, Buell U. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999;54:900 - 904.
  84. Crespo-Jara AA, Garcia MJ, Gimenez M, et al. Skeletal metastases in lung cancer: accuracy of 18FDG-PET in correlation with bone scintigraphy . J Nucl Med 1999;40:258P.
  85. Crespo-Jara AA, Gimenez M, Villar LM, et al. Evaluation of adrenal masses in lung cancer using 18FDG PET. J Nucl Med 2000;41:293P.
  86. Crippa F, Agresti R, Donne VD, et al. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: the experience of the National Cancer Institute of Milan [in Italian]. Tumori 1997;83:542 - 543.
  87. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998;39:4 - 8.
  88. Crowe J, Adler L, Shenk R, Sunshine J. Positron emission tomography and breast masses: comparison with clinical, mammographic, and pathological findings. Ann Surg Oncol. 1994;1:132 - 140.
  89. da Silva EA, Chugani DC, Muzik O, Chugani HT. Landau-Kleffner syndrome: metabolic abnormalities in temporal lobe are a common feature. J Child Neurol 1997;12:489 - 495.
  90. Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996;6:325 - 329.
  91. De Reuck J, Santens P, Decoo D, et al. Positron emission tomographic study of late-onset cryptogenic symptomatic seizures. Clin Neurol Neurosurg 1995;97:208 - 212.
  92. De Winter F, Van de Wiele C, Vogelaers D, et al. FDG PET is highly accurate in the diagnosis of chronic osteomyelitis in the central skeleton . J Nucl Med 2000;41:15P.
  93. de Wit M, Bender H, Dohmen BM, et al. Germ cell tumor: staging with FDG-PET. Pilot phase of the German multicenter trial . J Nucl Med 1999;40:256P.
  94. de Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 1997;8(suppl 1):57 - 60.
  95. Dehdashti F, Flanagan FL, Mortimer JE, Katzenellenbogen JA, Welch MJ, Siegel BA. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med 1999;26:51 - 56.
  96. Delbeke D, Lawrence SK, Abou-Khalil BW, Blumenkopf B, Kessler RM. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography. Invest Radiol 1996;31:261 - 266.
  97. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510 - 516.
  98. Delbeke D, Morgan DS, Kovalsky E, et al. 18F-fluorodeoxyglucose imaging with positron emission tomography in the follow-up of patients with lymphoma . J Nucl Med 2000;41:70P.
  99. Delbeke D, Morgan DS, Kovalsky E, et al. 18F-fluorodeoxyglucose imaging with positron emission tomography for initial staging of Hodgkin´s disease and lymphoma . J Nucl Med 2000;41:275P.
  100. Delbeke D, Rose D, Chapman W, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784 - 1791.
  101. Delbeke D, Vitola JV, Sandler MP, et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med. 1997;38:1196 - 1201.
  102. Deshmukh A, Scott JA, Palmer EL, Hochberg FH, Gruber M, Fischman AJ. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med 1996;21:720 - 725.
  103. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick MP. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. Chest 1993;104:997 - 1002.
  104. Dewan NA, Reeb SD, Gupta NC, Gobar LS, Scott WJ. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. Chest 1995;108:441 - 446.
  105. Di Martino E, Nowak B, Krombach GA, et al. Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET). Laryngo-Rhino-Otologie 2000;79:201 - 206.
  106. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1997;24:1342 - 1348.
  107. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm? Nuklearmedizin 1998;37:12 - 17.
  108. Dimitrakopoulou-Strauss A, Heichel T, Lehner B, Strauss LG. Positron emission tomography (PET) with 18F-deoxyglucose (FDG) in tumors of the skeleton system . J Nucl Med 2000;41:304P.
  109. Dimitrakopoulou-Strauss A, Schwarzbach M, Willeke F, Strauss LG. PET with FDG in soft tissue sarcomas . J Nucl Med 2000;41:303P.
  110. Dimitrakopoulou-Strauss A, Strauss LS, Goldschmidt H, Lorenz WJ, Maier-Borst W, van Kaick G. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas. Eur J Nucl Med 1995;22:434 - 442.
  111. Dittmann H, Dohmen BM, Soekler M, Kanz L, Bares R. Therapeutic relevance of FDG-PET in untreated Hodgkin´s disease and high-grade non-Hodgkin lymphoma . J Nucl Med 2000;41:71P.
  112. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). J Thorac Cardiovasc Surg 1995;110:130 - 140.
  113. Duhaylongsod FG, Lowe VJ, Patz EF Jr, Vaughn AL, Coleman RE, Wolfe WG. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348 - 1352.
  114. Duncan JD, Moss SD, Bandy DJ, et al. Use of positron emission tomography for presurgical localization of eloquent brain areas in children with seizures. Pediatr Neurosurg 1997;26:144 - 156.
  115. Eigtved A, Andersson AP, Dahlstróm K, et al. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 2000;27:70 - 75.
  116. Engel J Jr, Henry TR, Risinger MW, et al. Presurgical evaluation for partial epilepsy: relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG. Neurology 1990;40:1670 - 1677.
  117. Ericson K, Kihlström L, Mogard J, et al. Positron emission tomography using 18F-fluorodeoxyglucose in patients with stereotactically irradiated brain metastases. Stereotact Funct Neurosurg 1996;66.(suppl 1):214 - 224.
  118. Eubank WB, Mankoff DA, Shanley TJ, et al. Assessment of mediastinal lymph node metastasis in advanced breast cancer: comparison of FDG PET with CT . J Nucl Med 1999;40:17P - 18P.
  119. Farber L, Benard F, Machtay M, et al. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography. Laryngoscope 1999;109:970 - 975.
  120. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, Müller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468 - 1472.
  121. Fenchel S, Kotzerke J, Stöhr I, et al. Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F-18 fluorodeoxyglucose. Nuklearmedizin 1999;38:101 - 107.
  122. Ferrie CD, Maisey M, Cox T, et al. Focal abnormalities detected by 18FDG PET in epileptic encephalopathies [see comments]. Arch Dis Child 1996;75:102 - 107.
  123. Findlay M, Young H, Cunningham D, et al. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil [see comments]. J Clin Oncol 1996;14:700 - 708.
  124. Finke J, Buchmann I, Bares R, et al. (F-18)-FDG-PET in primary staging of malignant lymphoma: first results of a multicenter study . J Nucl Med 1999;40:61P.
  125. Fischbein NJ, AAssar OS, Caputo GR, et al. Clinical utility of positron emission tomography with 18F-fluoro-deoxy glucose in detecting residual/recurrent squamous cell carcinoma of the head and neck [see comments]. Am J Neuroradiol 1998;19:1189 - 1196.
  126. Flamen P, Stroobants S, Dupont P, et al. Additional value of positron emission tomography (PET) with fluorodeoxyglucose (FDG) in recurrent colorectal cancer: a study in 103 patients . J Nucl Med 1998;39:134P.
  127. Flamen P, Stroobants S, Van Cutsem E, et al. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. J Clin Oncol 1999;17:894 - 901.
  128. Flanagan F, Dedashti F, Siegel B, et al. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR 1997;168:417 - 424.
  129. Flanagan FL, Dehdashti F, Ogunbiyi OA, Kodner IJ, Siegel BA. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 1998;227:319 - 323.
  130. Fois A, Farnetani MA, Balestri P, et al. EEG, PET, SPET and MRI in intractable childhood epilepsies: possible surgical correlations. Child Nerv Syst 1995;11:672 - 678.
  131. Forster GJ, Kunkel M, Kutzner J, et al. Early monitoring of treatment response by (18F)FDG-PET in preoperatively irradiated advanced oral cancer . J Nucl Med 2000;41:113P.
  132. Franke C, Klapdor R, Meyerhoff K, Schauman M. 18-FDG positron emission tomography of the pancreas: diagnostic benefit in the follow-up of pancreatic carcinoma. Anticancer Res 1999;19:2437 - 2442.
  133. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2(18F)-fluoro-2-deoxy-D-glucose positron emission tomoraphy. Gut 1995;36:771 - 777.
  134. Fröhlich A, Diederichs C, Staib L, Vogel J, Beger H, Reske S. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999;40:250 - 255.
  135. Fujii H, Yasuda S, Ide M, et al. The usefulness of breast cancer screening using 18F FDG PET . J Nucl Med 2000;41:291P.
  136. Fukunaga T, Okazumi S, Koide Y, Isono K, Imazeki K. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 1998;39:1002 - 1007.
  137. Gamez C, Garcia-Velloso MJ, Villar LM, et al. 18F-FDG and 11C-methionine PET for evaluation of suspected recurrent colorectal cancer . J Nucl Med 2000;41:141P.
  138. Gauthier H, Levy E, Merlet P, Thirion P, Syrota A, Meignan M. High negative predictive value of FDG-PET for assessment of progressive disease in patients with soft tissue sarcoma . J Nucl Med 1999;40:259P.
  139. Gerber B, Vanoverschelde J, Bol A. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996;94:651 - 659.
  140. Gimenez M, Crespo-Jara AA, Villar L, et al. Preoperative and intraoperative uptake of 18FDG-PET in axillary metastases of breast cancer. A pathological correlation . J Nucl Med 1999;40:138P.
  141. Gliem I, Leutz M, Hellwig D, et al. Evaluation of malignancy-related pleural disease with FDG-positron emission tomography (PET) . Eur Respir J 1998;12:392S.
  142. Goldberg MA, Lee MJ, Fischman AJ, Mueller PR, Alpert NM, Thrall JH. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. RadioGraphics 1993;13:1047 - 1062.
  143. Grab D, Flock F, Stöhr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000;77:454 - 459.
  144. Greven KM, Keyes JW Jr, Williams DW III, McGuirt WF, Joyce WT III. Occult primary tumors of the head and neck: lack of benefit from positron emission tomography imaging with 2-(F-18)fluoro-2-deoxy-D-glucose. Cancer 1999;86:114 - 118.
  145. Greven KM, Williams DW III, Keyes JW Jr, et al. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 1994;29:841 - 845.
  146. Greven KM, Williams DW III, Keyes JW Jr, et al. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation [see comments]. Cancer 1994;74:1355 - 1359.
  147. Grigsby PW, Dehdashti F, Elbendary AA, et al. FDG-PET evaluation of primary carcinoma of the cervix. Gynecol Oncol 1999;72:457 - 458.
  148. Gritters LS, Francis IR, Zasadny KR, Wahl RL. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma. J Nucl Med 1993;34:1420 - 1427.
  149. Gropler R, Geltman E, Sampathkurmaran K. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993;22:1587 - 1597.
  150. Grünwald F, Kälicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547 - 1552.
  151. Grünwald F, Menzel C, Bender H, et al. Comparison of 18FDG-PET with 131I and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327 - 335.
  152. Grünwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312 - 319.
  153. Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske SN. Lymph node staging in non-small cell lung cancer: evaluation by (18F)FDG positron emission tomography (PET). Thorax 1997;52:438 - 441.
  154. Gupta NC, Bishop HA. Long-term outcome of patients with indeterminate lung nodules following management based on PET-FDG results . J Nucl Med 2000;41:76P.
  155. Gupta NC, Bishop HA, Graeber GM. Incidence and characteristics of falsely positive and negative lymph node on PET and CT in lung cancer staging . J Nucl Med 1999;40:57P.
  156. Gupta NC, Graeber G, Rogers J, Koay T, Bishop H. Relative utility of PET-FDG and CT scanning in preoperative TNM staging of lung cancer patients . J Nucl Med 1998;39:80P.
  157. Gupta NC, Graeber GM, Bishop HA, Raylman RR. Improved pre-operative staging of primary lung cancer by PET-FDG imaging . J Nucl Med 1997;38:243P - 244P.
  158. Gupta NC, Graeber GM, Bishop HA, Stephens TS. Comparative efficacy of FDG-PET in evaluation of small (less than 3 cm) and large (greater than 3 cm) pulmonary (PUL) and lymph node (LN) lesions . J Nucl Med 1997;38:79P.
  159. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET [see comments]. J Nucl Med 1996;37:943 - 948.
  160. Gupta NC, Nicholson P, Bloomfield SM. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors. Ann Surg 1999;230:202 - 206.
  161. Gupta NC, Tamim WZ, Bishop HA. Is there any incremental value of routine lymph node sampling using mediastinoscopy and/or thoracotomy or open biopsy for management of lung cancer patients following whole body PET ? J Nucl Med 2000;41:76P.
  162. Gupta-Burt S, Marcus E, Coon J, et al. The role of positron-emission tomography (PET) in the assessment of pathologic response to neoadjuvant chemotherapy with doxorubicin and docetaxel in patients with locally advanced breast cancer . Eur J Cancer 1999;35:S316.
  163. Haase A, Lauer I, Meller B, Richter E, Baehre MH. Feasibility of detecting unknown primary tumors with gamma camera coincidence PET . J Nucl Med 2000;41:296P.
  164. Haberkorn U, Strauss LG, Dimitrakopoulou A, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12 - 17.
  165. Haenggeli CA, Dulguerov P, Slosman D, et al. Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma [in German]. Schweiz Med Wochenschr. 2000;116.(suppl):8S - 11S.
  166. Hagberg RC, Segall GM, Stark P, Burdon TA, Pompili MF. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography. Eur J Cardiothorac Surg 1997;12:92 - 97.
  167. Hain SF, O´Doherty MJ, Huddart RA, Leslie MD, Timothy AR, Harper PG. The value of FDG-PET in recurrent testicular carcinoma . J Nucl Med 1999;40:105P.
  168. Hain SF, O´Doherty MJ, Leslie MD, Timothy AR. Staging of testicular carcinoma with FDG-PET . J Nucl Med 1999;40:256P.
  169. Hain SF, O´Doherty MJ, Lucas JD, Smith MA. Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma. Nucl Med Commun 1999;20:845 - 848.
  170. Hanasono MM, Kunda LD, Segall GM, Ku GH, Terris DJ. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer. Laryngoscope 1999;109:880 - 885.
  171. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998;39:990 - 995.
  172. Harms W, Bares R, Kamps H, Gronimus R, Boeckmann W, Jake G. Therapy control of metastatic testicular carcinoma with F18-DOG PET . J Nucl Med 1995;36:198P.
  173. Harrison J, Ali A, Bonomi P, Prinz R. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy. Am Surg 2000;66:432 - 437.
  174. Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen positron emission tomography and biopsy correlation. Clin Nucl Med 1996;21:704 - 713.
  175. Hathaway PB, Mankoff DA, Maravilla KR, et al. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience. Radiology 1999;210:807 - 814.
  176. Heicappell R, Mueller-Mattheis V, Reinhardt M, et al. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-(18F)-2-deoxy-D-glucose. Eur Urol 1999;36:582 - 587.
  177. Heinz R, Ferris N, Lee EK, et al. MR and positron emission tomography in the diagnosis of surgically correctable temporal lobe epilepsy. Am J Neuroradiol 1994;15:1341 - 1348.
  178. Helveston W, Gilmore R, Roper S, et al. Intractable temporal lobe epilepsy: comparison of positron emission tomography with qualitative and quantitative MR. Am J Neuroradiol 1996;17:1515 - 1521.
  179. Henze M, Brix G, Knopp M, et al. Functional breast imaging: comparison of 18F-fluorodeoxyglucose (FDG) PET and pharmacokinetic MR mapping (DMRI) . J Nucl Med 2000;41:290P.
  180. Henze M, Mohammed A, Mier W, et al. Pretreatment studies of 18F-fluorodeoxyglucose (FDG), 123I-(alpha)-methlytyrosine (IMT) and 99mTc-sestamibi uptake in hypopharynx-larynx-carcinomas . J Nucl Med. 2000;41:142P.
  181. Herholz K, Perani D, Salmon E, et al. Comparability of FDG PET studies in probable Alzheimer´s disease. J Nucl Med 1993;34:1460 - 1466.
  182. Hicks RJ, Binns D, Kalff V, et al. The utility of flourine-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for restaging of non-small cell lung cancer (NSCLC): Analysis of management change and survival in 63 consecutive patients . J Nucl Med 2000;41:75P.
  183. Higashi K, Nishikawa T, Seki H, et al. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer. J Nucl Med 1998;39:9 - 15.
  184. Higashi K, Ueda Y, Kodama Y, et al. Comparison of 18F FDG PET and 201Tl SPECT in evaluation of pulmonary nodules . J Nucl Med 2000;41:297P.
  185. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 1999;40:1424 - 1433.
  186. Hoda S, Ardakani N, Hawkins RA. Significance of PET-FDG in comparison with 131I WBS and serum Tg in detection of recurrent and metastatic papillary thyroid carcinoma . J Nucl Med 2000;41:312P.
  187. Hoffman J, Welsh-Bohmer K, Hanson M, et al. FDG-PET imaging in pathologically verified dementia. J Nucl Med 2000;41:1920 - 1928.
  188. Hoffman JM, Waskin HA, Schifter T, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567 - 575.
  189. Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999;10:1185 - 1189.
  190. Hoh C, Glaspy J, Rosen P, et al. Whole-body FDG-PET imaging for staging of Hodgkin´s disease and lymphoma. J Nucl Med 1997;38:343 - 348.
  191. Hoh CK, Chap L, Glaspy JA, Bui S, Czernin J, Phelps ME. Prognostic value of whole body FDG PET in breast cancer patients undergoing chemotherapy . J Nucl Med 1998;39:254P.
  192. Hoh CK, Figlin RA, Belldegrun A, et al. Evaluation of renal cell carcinoma with whole body FDG PET . J Nucl Med 1996;37:141P.
  193. Hoh CK, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using 2-(18F)fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 1993;17:582 - 589.
  194. Hoh CK, Rosen PJ, Belldegrun A, Moon DH, Maddahi J, Phelps ME. Quantitative and whole-body FDG PET in the evaluation of suramin therapy in patients with metastatic prostate cancer . J Nucl Med 1996;37:267P.
  195. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg 1998;227:764 - 771.
  196. Holopainen IE, Lundbom NM, Metsähonkala EL, et al. Temporal lobe pathology in epilepsy: proton magnetic resonance spectroscopy and positron emission tomography study. Pediatr Neurol 1997;16:98 - 104.
  197. Holthoff VA, Herholz K, Berthold F, et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment. Cancer 1993;72:1394 - 1403.
  198. Hölzer T, Herholz K, Jeske J, Heiss WD. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma. J Comput Assist Tomogr 1993;17:681 - 687.
  199. Hsueh EC, Gupta RK, Glass EC, Yee R, Qi K, Morton DL. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma. J Am Coll Surg 1998;187:191 - 197.
  200. Hübner K, McDonald T, Niethammer J, Smith G, Gould H, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using (2-(18F)FDG). Gynecol Oncol 1993;51:197 - 204.
  201. Hübner KF, Buonocore E, Gould HR, et al. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images. Clin Nucl Med 1996;21:941 - 949.
  202. Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW. Characterization of chest masses by FDG positron emission tomography. Clin Nucl Med. 1995;20:293 - 298.
  203. Hustinx R, Smith RJ, Benard F, Bhatnagar A, Alavi A. Can the standardized uptake value characterize primary brain tumors on FDG-PET? Eur J Nucl Med 1999;26:1501 - 1509.
  204. Hwang KH, Park CH, Kim HC, Kim HS, Yoon SN, Kim S. Imaging of malignant lymphomas with 18F-FDG coincidence detection PET (CoDe-PET) . J Nucl Med 2000;41:278P.
  205. Imdahl A, Nitzsche E, Krautmann F, et al. Evaluation of positron emission tomography with 2-(18F)fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194 - 199.
  206. Imdahl A, Reinhardt MJ, Nitzsche EU, et al. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 2000;385:129 - 134. 10796051&;kyD(d)
  207. Inagaki K, Morita T, Fujii K, Kosaka N, Hara T. Mediastinal lymph node staging in non-small cell lung cancer using PET with C-11 choline and F-18 FDG . J Nucl Med 1999;40:59P - 60P.
  208. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 1995;195:345 - 352.
  209. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995;36:788 - 793.
  210. Inubushi M, Ishida Y, Fukuchi K, Fukushima K, Sasako K. Myocardial viability assessment using 18F FDG gated PET . J Nucl Med 2000;41:157P.
  211. Israel O, Yefremov N, Mor M, et al. 67Ga scintigraphy and 18F FDG coincidence imaging in the evaluation of lymphoma . J Nucl Med 2000;41:141P.
  212. Jacobson AF, Maisey MN, Fogelman I. Yield of FDG-PET scans for identifying active malignancy in patients with elevated tumour markers . J Nucl Med 1999;40:101P - 102P.
  213. Jacobson AF, Maisey MN, Fogelman I, Kuhn D. Yield of FDG-PET scanning as a routine follow-up exam in patients with malignancy . J Nucl Med 2000;41:304P.
  214. Jadvar H, Fischman AJ. Clinical impact of FDG PET on the management of patients with pancreatic carcinoma: comparison with CT and CA19-9 serology . J Nucl Med 1999;40:104P.
  215. Jadvar H, Johnson DL, Segall GM. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 2000;25:48 - 51.
  216. Jadvar H, McDougall IR, Segall GM. Evaluation of suspected recurrent papillary thyroid carcinoma with (18F)fluorodeoxyglucose positron emission tomography. Nucl Med Commun 1998;19:547 - 554.
  217. Jansson T, Westlin JE, Ahlström H, Lilja A, Långström B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995;13:1470 - 1477.
  218. Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK. Use of (18F)fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors. Ann Neurol 1993;33:540 - 548.
  219. Jerusalem G, Beguin Y, Fasotte M, et al. Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin´s disease and non-Hodgkin´s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429 - 433.
  220. Jerusalem G, Beguin Y, Fassotte MF, et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin´s lymphoma. Haematologica 2000;85:613 - 618.
  221. Jerusalem G, Warland V, Najjar F, et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin´s disease and non-Hodgkin´s lymphoma. Nucl Med Commun 1999;20:13 - 20.
  222. Kahn D, Follett KA, Bushnell DL, et al. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET. AJR 1994;163:1459 - 1465.
  223. Kalff V, Hicks RJ, McManus M, et al. The clinical impact of PET scanning in patients with lung cancer: a prospective . J Nucl Med 1998;39:249P.
  224. Karlan BY, Hawkins R, Hoh C, et al. Whole-body positron emission tomography with 2-(18F)-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175 - 181.
  225. Kato T, Tsukamoto E, Shiga T, et al. Preliminary results of whole body FDG-PET in biliary carcinoma . J Nucl Med 2000;41:298P.
  226. Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE. Local recurrence of rectal cancer: evaluation of F-18 fluorodeoxyglucose PET imaging. Abdom Imaging 1997;22:332 - 337.
  227. Kerrou K, Montravers F, Grahek D, Younsi N, de Beco V, Talbot JN. Follow-up of ovarian cancer using (18F)-FDG scan with a dual-head coincidence gamma camera (CDET) . J Nucl Med 2000;41:302P.
  228. Keyes JW Jr, Chen MY, Watson NE Jr, Greven KM, McGuirt WF, Williams DW III. FDG PET evaluation of head and neck cancer: value of imaging the thorax. Head Neck 2000;22:105 - 110.
  229. Kim DG, Kim CY, Paek SH, et al. Whole-body (18F)FDG PET in the management of metastatic brain tumours. Acta Neurochirurg 1998;140:665 - 684.
  230. Kim JH, Choi CW, Kim BG, et al. FDG-PET in patients with cervical cancer of uterus: experience in patients with clinically no evidence of disease . J Nucl Med 2000;41:300P.
  231. Kim S, Park CH, Han MH, et al. How useful is 18F-FDG coincidence detection positron emission tomography in the staging of lung cancer? J Nucl Med 2000;41:296P - 297P.
  232. Kincaid PK, El-Saden SM, Park SH, Goy BW. Cerebral gangliogliomas: preoperative grading using FDG-PET and 201Tl-SPECT [see comments]. Am J Neuroradiol 1998;19:801 - 806.
  233. Kluge R, Berr F, Schmidt F, et al. Value of 18F-FDG PET in detection and staging of perihilar cholangiocarcinoma . J Nucl Med 2000;41:36P.
  234. Klutmann S, Bohuslavizki KH, Buchert R, et al. Impact of 18F-FDG-PET in patients with cancer of unknown primary . J Nucl Med 1999;40:259P.
  235. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy. Chest 1996;109:982 - 988.
  236. Knuuti M, Saraste M, Nuutila P. Myocardial viability: fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization. Am Heart J 1994;127:785 - 796.
  237. Kole A, Plukker J, Nieweg O, Vaalburg W. Positron emission tomography for staging of gastroesophageal malignancy. Br J Cancer 1998;78:521 - 527.
  238. Kole AC, Nieweg OE, Pruim J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer 1998;82:1160 - 1166.
  239. Kole AC, Nieweg OE, Pruim J, et al. Whole-body PET with FDG: detection of unknown primary tumors . J Nucl Med 1995;36:57P.
  240. Kole AC, Nieweg OE, van Ginkel RJ, et al. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using (18F)fluorodeoxyglucose. Ann Surg Oncol 1997;4:57 - 63.
  241. Kostakoglu L, Leonard JP, Coleman M, Kuji I, Vallabhajosula S, Goldsmith SJ. Evaluation of FDG-PET in the detection of bone marrow involvement in lymphoma . J Nucl Med 2000;41:71P.
  242. Kostakoglu L, Leonard JP, Coleman M, Kuji I, Vallabhajosula S, Goldsmith SJ. Comparison of FDG-PET and 67Ga SPECT in the staging of lymphoma . J Nucl Med 2000;41:118P.
  243. Kosuda S, Grossman HB, Kison PV, Wahl RL. Preliminary FDG-PET study in patients with bladder cancer . J Nucl Med 1996;37:260P.
  244. Kraemer DLA, Griebel ML, Lee N, Friedman AH, Radtke RA. Surgical outcome in patients with epilepsy with occult vascular malformations treated with lesionectomy. Epilepsia 1998;39:600 - 607.
  245. Kubik-Huch RA, Dörffler W, von Schulthess GK, et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol 2000;10:761 - 767.
  246. Kuehnel G, Rades D, Wildfang I, et al. Whole-body positron emission tomography (PET) with 18F-FDG in patients with cancer of unknown primary . J Nucl Med 2000;41:300P.
  247. Kunkel M, Kuffner HD, Reichert TE, Benz P, Förster GJ, Wagner W. (18F)-2-fluorodeoxyglucose PET. Prospects for secondary prevention of mouth cavity carcinoma [in German]. Mund Kiefer Gesichtschirurg 2000;4:105 - 110.
  248. Kurtaran A, Becherer A, Poetzi C, et al. Limited value of (18F)FDG-PET in localizing of recurrent/metastatic medullary thyroid carcinoma (MTC) . J Nucl Med 2000;41:308P.
  249. Kutlu CA, Pastorino U, Maisey M, Goldstraw P. Selective use of PET scan in the preoperative staging of NSCLC. Lung Cancer 1998;21:177 - 184.
  250. Lai DT, Fulham M, Stephen MS, et al. The role of whole-body positron emission tomography with (18F) fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. Arch Surg 1996;131:703 - 707.
  251. Lang O, Bihl H. Carcinoma of unknown primary (CUP): value of whole-body F-18-FDG-PET for detection of the primary tumor . J Nucl Med 1999;40:259P.
  252. Lang O, Brouwers AH, Mergenthaler HG, Doerr U, Bihl H. Value of whole-body 18F-FDG-PET in metastatic renal cell carcinoma: correlation with tumor aggressiveness ? J Nucl Med 2000;41:117P.
  253. Lang O, Doerr U, Merkle P, Bihl H. Whole-body 18F-FDG-PET in patients with suspected recurrence of colorectal cancer: a comparison with CT and MRI . J Nucl Med 2000;41:35P.
  254. Lang O, Doerr U, Schneider K, Hagen R, Bihl H. Cervical lymph node staging in patients with head and neck cancer: a comparison between 18F-FDG-PET and ultrasound . J Nucl Med 2000;41:32P.
  255. Laningham FH, Smith GT, Hanna WT, Hubner KF. The impact of whole body FDG PET on the management of patients with malignant melanoma . Clin Positron Imaging 1998;1:262.
  256. Lapela M, Eigtved A, Jyrkkiö S, et al. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer. Eur J Cancer 2000;36:858 - 867.
  257. Lapela M, Grénman R, Kurki T, et al. Head and neck cancer: detection of recurrence with PET and 2-(F-18)fluoro-2-deoxy-D-glucose. Radiology 1995;197:205 - 211.
  258. Lassen U, Daugaard G, Eigtved A, Damgaard K, Friberg L. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT). Eur J Cancer 1999;35:1076 - 1082.
  259. Leiderman DB, Balish M, Sato S, et al. Comparison of PET measurements of cerebral blood flow and glucose metabolism for the localization of human epileptic foci. Epilepsy Res 1992;13:153 - 157.
  260. Lenzo NP, Shulkin B, Castle VP, Hutchinson RJ. FDG PET in childhood soft tissue sarcoma . J Nucl Med 2000;41:96P.
  261. Lewis P, Griffin S, Marsden P, et al. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 1994;344:1265 - 1266.
  262. Li PY, Mozley PD, Zhuang HM, et al. Effectiveness of FDG PET in the detection of recurrent squamous cell carcinoma of the head and neck . J Nucl Med 2000;41:32P.
  263. Lin PC, Chu J, Pocock N. 18F fluorodeoxyglucose imaging with coincidence dual-head gamma camera (hybrid FDG-PET) for staging of lymphoma: comparison with 67Ga scintigraphy . J Nucl Med 2000;41:118P.
  264. Lin PC, Chu J, Pocock N, Quach T, Sorensen B. F-18 FDG imaging with coincidence dual-head gamma camera (co-PET) in staging of lymphoma: comparison with CT and gallium scans . J Nucl Med 1999;40:62P.
  265. Lindholm P, Leskinen-Kallio S, Minn H, et al. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer. J Nucl Med 1993;34:1711 - 1716.
  266. Liu RS, Chu LS, Lee CH, et al. Limited usefulness of (11C)acetate whole body PET in patients with thyroid cancer . J Nucl Med 2000;41:310P.
  267. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O´Doherty MJ. A six-hour study of soft tissue masses using FDG PET . J Nucl Med 1998;39:255P.
  268. Lodge MA, Lucas JD, Marsden PK, Cronin BF, O´Doherty MJ, Smith MA. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22 - 30.
  269. Lonneux M, Borbath I, Bausart R, Pauwels S. The role of PET-18FDG in detecting distant recurrence of breast cancer . J Nucl Med 1999;40:250P.
  270. Lonneux M, Delval D, Bausart R, et al. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer. Nucl Med Commun 1998;19:1047 - 1054.
  271. Lowe V, Boyd J, Dunphy F, et al. Surveillance for recurrent head and neck cancer using positron emission tomography. J Clin Oncol 2000;18:651 - 658.
  272. Lowe V, Dunphy F, Varvares M, et al. Evaluation of chemotherapeutic response in patients with advanced head and neck cancer using (F-18) fluorodeoxyglucose positron emission tomography. Head Neck 1997;19:666 - 674.
  273. Lowe VJ, Fletcher JW, Gobar L, et al. Prospective investigation of positron emission tomography in lung nodules. J Clin Oncol 1998;16:1075 - 1084.
  274. Lowe VJ, Kim H, Boyd JH, Eisenbeis JF, Dunphy FR, Fletcher JW. Primary and recurrent early stage laryngeal cancer: preliminary results of 2-[fluorine 18]fluoro-2-deoxy-D-glucose PET imaging. Radiology 1999;212:799 - 802.
  275. Lowe VJ, Naunheim KS, Dunphy FR, Kim HJ, Fletcher JW. Evaluation of diagnostic testing discrepancies in the management of lung cancer: a review incorporating (F-18)FDG-PET imaging . J Nucl Med 1998;39:248P.
  276. Lucas JD, O´Doherty MJ, Cronin BF, et al. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography. Br J Surg 1999;86:550 - 556.
  277. Lucas JD, O´Doherty MJ, Wong JC, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg. [British volume] 1998;80:441 - 447.
  278. Lucignani G, Paolini G, Landoni C. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxybutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874 - 881.
  279. Lucignani G, Tassi L, Fazio F, et al. Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: are the electric and metabolic findings related? Eur J Nucl Med 1996;23:1498 - 1507.
  280. Luketich JD, Friedman DM, Weigel TL, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133 - 1137.
  281. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 1997;64:765 - 769.
  282. Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-(18F)-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16:1770 - 1776.
  283. Maes A, Borgers M, Flameng W. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT: correlation with histologic and positron emission tomographic studies and functional follow up. J Am Coll Cardiol 1997;29:62 - 68.
  284. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg 1999;40:741 - 748.
  285. Maisey M, Wahl R, Barrington S. Atlas of Clinical Positron Emission Tomography London, UK: Arnold, Hodder Headline Group; 1999.
  286. Maisey NR, Hill ME, Webb A, et al. Are 18-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses? Eur J Cancer 2000;36:200 - 206.
  287. Maldonado A, Sancho F, Calvo F, et al. The role of FDG-PET in diagnosing suspected tumor recurrence based on increased levels of plasma markers . Clin Positron Imaging 1998;1:246.
  288. Manolidis S, Donald PJ, Volk P, Pounds TR. The use of positron emission tomography scanning in occult and recurrent head and neck cancer. Acta Otolaryngol 1998;534.(suppl):1 - 11.
  289. Markand ON, Salanova V, Worth R, Park HM, Wellman HN. Comparative study of interictal PET and ictal SPECT in complex partial seizures. Acta Neurol Scand. 1997;95:129 - 136.
  290. Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999;212:803 - 809.
  291. Martin L, Fazel A, Burton F, Fletcher JW. Performance of dedicated, non-attenuation corrected FDG-PET in diagnosis and staging of pancreatic cancer (PCa) . J Nucl Med 2000;41:35P - 36P.
  292. Martinez-Lazaro R, Cortes-Blanco A, Zhuang HM, Alavi AA. Diagnostic performance of whole-body FDG-PET and CT imaging in malignant lymphomas . J Nucl Med 2000;41:277P.
  293. Matthies A, Smith RJ, Cuchiara AJ, Alavi AA. Dual time point 18FDG-PET imaging for the differentiation between benign and malignant pulmonary nodules . J Nucl Med 2000;41:293P.
  294. Melchior SW, Fichtner J, Jones J, et al. Changes in fluorodeoxyglucose (FDG) uptake measured by positron emission tomography (PET) in prostate cancer (CaP) patients following androgen withdrawal . J Urol 1999;161:297.
  295. Meltzer CC, Luketich JD, Friedman D, et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer. Comparison with computed tomography. Clin Nucl Med. 2000;25:882 - 887.
  296. Menda Y, Bushnell DL, Madsen MT, Kernstine KH, McLaughlin K, Hichwa RD. Retrospective analysis of standardized uptake values of lung masses with 18F FDG PET . J Nucl Med 2000;41:295P.
  297. Meta J, Valk P, Ariannejad M, et al. Impact of FDG-PET on management of patients with colorectal cancer . J Nucl Med 2000;41:299P.
  298. Mielke R, Heiss WD. Positron emission tomography for diagnosis of Alzheimer´s disease and vascular dementia. J Neural Transm 1998;53:237 - 250.
  299. Mielke R, Pietrzyk U, Jacobs A, et al. HMPAO SPET and FDG PET in Alzheimer´s disease and vascular dementia: comparison of perfusion and metabolic pattern [see comments]. Eur J Nucl Med 1994;21:1052 - 1060.
  300. Mielke R, Schroeder R, Fink GR, Kessler J, Herholz K, Heiss WD. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer´s disease. Acta Neuropathol 1996;91:174 - 179.
  301. Mikhaeel NG, Timothy AR, Hain SF, O´Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol 2000;11.(suppl 1):147 - 150.
  302. Montravers F, Grahek D, Kerrou K, de Beco V, Younsi N, Talbot JN. Comparison of FDG scan on a dual-head coincidence gamma camera (CDET) and conventional imaging for the diagnosis of recurrence of colorectal cancer . J Nucl Med 2000;41:300P.
  303. Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-(F-18)fluoro-D-glucose (FDG) PET in nodal staging. Radiology 1997;203:795 - 800.
  304. Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998;206:475 - 481.
  305. Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999;40:1407 - 1413.
  306. Moon D, Maddahi J, Silverman D, Glaspy J, Phelps M, Hoh C. Accuracy of whole body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431 - 435.
  307. Mruck S, Baum RP, Rinne D, Hoer G. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics. Anticancer Res 1999;19:2685 - 2690.
  308. Mueller SP, Goerges R, Brandt-Mainz K, Bockisch A. The role of FDG-PET and 201Tl imaging as a preoperative diagnostic tool in recurrent Hürthle cell carcinoma of the thyroid . J Nucl Med 2000;41:306P.
  309. Mukahira K, Oguni H, Awaya Y, et al. Study on surgical treatment of intractable childhood epilepsy. Brain Dev 1998;20:154 - 164.
  310. Musholt TJ, Musholt PB, Dehdashti F, Moley JF. Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: a clinical and molecular study. Surgery (St. Louis) 1997;122:1049 - 1061.
  311. Myers LL, Wax MK. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer. J Otolaryngol 1998;27:342 - 347.
  312. Nakamoto Y, Higashi T, Sakahara H, et al. Contribution of PET in the detection of liver metastases from pancreatic tumours. Clin Radiol 1999;54:248 - 252.
  313. Nakamoto Y, Saga T, Ishimori T, et al. Clinical contribution of FDG-PET for follow-up patients with gynecological malignancies . J Nucl Med 2000;41:301P.
  314. Nettelbladt OS, Sundin AE, Valind SO, et al. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. J Nucl Med 1998;39:640 - 647.
  315. Newman JS, Francis IR, Kaminski MS, Wahl RL. Imaging of lymphoma with PET with 2-(F-18)-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 1994;190:111 - 116.
  316. Nguyen A, Akhurst T, Larson S, Coit D, Brady M. PET Scanning with 18F2-fluoro-2-deoxy-D-glucose(FDG) in patients with melanoma: benefits and limitations. Clin Positron Imaging 1999;2:93 - 98.
  317. Nieweg O, Kim E, Wong W, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993;71:3920 - 3925.
  318. Nieweg OE, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med 1996;37:257 - 261.
  319. Nitzsche EU, Hoh CK, Dalbohm NM, et al. Whole body positron emission tomography in breast cancer [in German]. Rofo Fortschr Geb Rontgenstr 1993;158:293 - 298.
  320. Nitzsche EU, Simon GH, Krautmann F, et al. Is FDG PET indicated when cancer disease of the pancreas is diagnosed based on CT ? J Nucl Med 1997;38:144P.
  321. Noh D, Yun I, Kim J, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg. 1998;22:223 - 228.
  322. Noh DY, Yun IJ, Kang HS, et al. Detection of cancer in augmented breasts by positron emission tomography. Euro J Surg. 1999;165:847 - 851.
  323. Nowak B, Di Martino E, Jänicke S, et al. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI. Nuklearmedizin 1999;38:312 - 318.
  324. Nunez RF, Yeung HW, Macapinlac HA, Larson SM. Does post radiation therapy change in the lung affect the accuracy of FDG-PET in the evaluation of tumor recurrence in lung cancer ? J Nucl Med 1999;40:234P.
  325. Nuutinen J, Leskinen S, Elomaa I, et al. FDG-PET imaging of residual testicular cancer after chemotherapy . J Nucl Med 1996;37:256P.
  326. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997;4:613 - 620.
  327. Orino K, Kawamura M, Hatazawa J, Suzuki I, Sazawa Y. Efficacy of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in diagnosis of pulmonary nodules [in Japanese]. Jpn J Thorac Cardiovasc Surg 1998;46:1267 - 1274.
  328. Oriuchi N, Ichikawa A, Koyama K, et al. Clinical significance of L-(3-18F)- alpha-methyl tyrosine PET studies in intracranial and intrathoracic tumor: a comparative study with 18F-FDG PET . J Nucl Med 2000;41:291P - 292P.
  329. Oyama N, Akino H, Suzuki Y, et al. The increased accumulation of (18F)fluorodeoxyglucose in untreated prostate cancer. Jpn J Clin Oncol 1999;29:623 - 629.
  330. Oyama N, Akino H, Suzuki Y, et al. FDG-PET for evaluating the effectiveness of endocrine therapy for prostate cancer . J Nucl Med 1999;40:256P - 257P.
  331. Oyen WJ, Neeleman N, Ruers TJ, Jager GJ, Wobbes T, Corstens FH. FDG-PET in metastasized colorectal carcinoma . J Nucl Med. 2000;41:35P.
  332. Pai M, Park CH, Suh JH, Koh JH. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer. Clin Nucl Med 1999;24:495 - 500.
  333. Palmedo H, Bender H, Grünwald F, Mallmann P, Krebs D, Biersack H. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. Eur J Nucl Med 1997;24:1138 - 1145.
  334. Paquet P, Henry F, Belhocine T, et al. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging. Dermatology 2000;200:167 - 169.
  335. Patz EF Jr, Lowe VJ, Goodman PC, Herndon J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest 1995;108:1617 - 1621.
  336. Patz EF Jr, Lowe VJ, Hoffman JM, et al. Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. Radiology 1993;188:487 - 490.
  337. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-(F-18)-12-deoxy-D-glucose. Radiology 1994;191:379 - 382.
  338. Paulus P, Sambon A, Vivegnis D, et al. 18FDG PET for the assessment of primary head and neck tumors: clinical, computed tomography, and histopathological correlation in 38 patients. Laryngoscope 1998;108:1578 - 1583.
  339. Pawlik G, Holthoff VA, Kessler J, et al. Positron emission tomography findings relevant to neurosurgery for epilepsy. Acta Neurochirurg 1990;50. (suppl):84 - 87.
  340. Peterson LM, Graham MM, Hayward RM, Yeung RS, Hansen PD. FDG PET identify residual or recurrent disease following local ablation of liver metastases . J Nucl Med 2000;41:287P.
  341. Präuer HW, Weber WA, Römer W, Treumann T, Ziegler SI, Schwaiger M. Controlled prospective study of positron emission tomography using the glucose analogue (18F)fluorodeoxyglucose in the evaluation of pulmonary nodules. Br J Surg 1998;85:1506 - 1511.
  342. Que TH, Plukker JT, Vaalburg W. Staging of gastroesophageal cancer with PET using 11C choline and 18F FDG . J Nucl Med 2000;41:141P.
  343. Raja S, Fernandez-Vicioso E, Suh JH, et al. Brain tumor recurrence versus radiation necrosis: role of Tc-99m MIBI compared to FDG PET . J Nucl Med 1997;38:153P.
  344. Rakotonirina H, Delahaye N, Crestani B, et al. Preoperative staging of patients (PTS) with non-small cell lung cancer (NSCLC) using 18FDG imaging: comparison of dual-head coincidence (DHC) gamma-camera versus dedicated PET . J Nucl Med 2000;41:292P.
  345. Rankin SC, Taylor H, Cook GJ, Mason R. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 1998;53:659 - 665.
  346. Rege S, Maass A, Chaiken L, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047 - 3058.
  347. Rege SD, Hoh CK, Glaspy JA, et al. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer 1993;72:82 - 90.
  348. Richter J, Garcia-Velloso M, Perez-Equiza C, et al. PET-FDG versus CT in the staging and detection of relapse in patients with Hodgkin´s disease or non-Hodgkin lymphoma: two years experience . Clin Positron Imaging 1998;1:248.
  349. Rinne D, Baum RP, Hör G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82:1664 - 1671.
  350. Rintahaka PJ, Chugani HT. Clinical role of positron emission tomography in children with tuberous sclerosis complex. J Child Neurol 1997;12:42 - 52.
  351. Römer W, Avril N, Dose J, et al. Metabolic characterization of ovarian tumors with positron emission tomography and F-18 fluorodeoxyglucose. Rofo Fortschr Geb Rontgenstr. 1997;166:62 - 68.
  352. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study. J Clin Oncol 1999;17:41 - 45.
  353. Rostom AY, Powe J, Kandil A, et al. Positron emission tomography in breast cancer: a clinicopathological correlation of results. Br J Radiol 1999;72:1064 - 1068.
  354. Rozental JM, Cohen JD, Mehta MP, Levine RL, Hanson JM, Nickles RJ. Acute changes in glucose uptake after treatment: the effects of carmustine (BCNU) on human glioblastoma multiforme. J Neuro-Oncol 1993;15:57 - 66.
  355. Ruhlmann J, Schomburg A, Bender H, et al. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice. Dis Colon Rectum 1997;40:1195 - 1204.
  356. Ryu JS, Choi NC, Fischman AJ. FDG-PET in evaluating therapeutic effect and restaging of non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology . J Nucl Med 1999;40:246P.
  357. Safa AA, Tran LM, Rege S, et al. The role of positron emission tomography in occult primary head and neck cancers [see comments]. Cancer J Sci Am 1999;5:214 - 218.
  358. Salanova V, Markand O, Worth R, et al. Presurgical evaluation and surgical outcome of temporal lobe epilepsy. Pediatr Neurol 1999;20:179 - 184.
  359. Salanova V, Markand O, Worth R, et al. FDG-PET and MRI in temporal lobe epilepsy: relationship to febrile seizures, hippocampal sclerosis and outcome. Acta Neurol Scand 1998;97:146 - 153.
  360. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer´s disease with PET. J Nucl Med 1994;35:391 - 398.
  361. Sanz G, Robles JE, Giménez M, et al. Positron emission tomography with 18-fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. Br J Urol Int 1999;84:1028 - 1031.
  362. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996;23:741 - 747.
  363. Saunders CAB, Dussek JE, O´Doherty MJ, Maisey MN. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790 - 797.
  364. Savic I, Ingvar M, Stone-Elander S. Comparison of [11C]flumazenil and (18F)FDG as PET markers of epileptic foci. J Neurol Neurosurg Psychiatry 1993;56:615 - 621.
  365. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996;153:417 - 421.
  366. Scheidhauer K, Scharl A, Pietrzyk U, et al. Qualitative (18F) FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med 1996;23:618 - 623.
  367. Schelling M, Avril N, Nährig J, et al. Positron emission tomography using (18F)fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689 - 1695.
  368. Schiepers C, Meta J, Yap CS, et al. Characterization of solitary pulmonary nodules and lung cancer with FDG-PET . J Nucl Med 2000;41:296P.
  369. Schiepers C, Penninckx F, De Vadder N, et al. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur J Surg Oncol 1995;21:517 - 522.
  370. Schiepers C, Yap CS, Meta J, et al. Staging of recurrent lung cancer: value of FDG-PET in therapy selection and management of patients . J Nucl Med 2000;41:75P.
  371. Schiepers C, Yap CS, Silverman DH, et al. Staging of newly diagnosed lung cancer: impact of FDG-PET on patient management . J Nucl Med 2000;41:109P.
  372. Schirrmeister H, Guhlmann A, Kotzerke J, et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol 1999;17:2381 - 2389.[Abstract/Full Text]
  373. Schirrmeister H, Guhlmann CA, Diederichs CD, Trager H, Reske SN. Planar bone imaging vs 18F-PET in patients with cancer of the prostate, thyroid and lung . J Nucl Med 1998;39:113P - 114P.
  374. Schirrmeister HH, Kuehn T, Buck AK, Reske SN. FDG-PET in preoperative staging of breast cancer . J Nucl Med 2000;41:28P.
  375. Schirrmeister HH, Staib L, Buck AK, Guhlmann CA, Reske SS. FDG-PET in patients with suspected recurrence of colorectal cancer. Is there a contribution to surgical decision finding ? J Nucl Med 2000;41:297P.
  376. Schlüter B, Grimm-Riepe C, Beyer W, Lübeck M, Schirren-Bumann K, Clausen M. Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer. Langenbecks Arch Surg 1998;383:187 - 189.
  377. Schöder H, Campisi R, Ohtake T, et al. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction. J Am Coll Cardiol 1999;33:1328. - 1337.
  378. Schoenberger JA, Bergner U, Maag K, Eilles C. Comparison of hybrid PET system and dedicated PET-scanner in patients with colon cancer and indeterminate liver lesion . J Nucl Med 2000;41:291P.
  379. Schulte M, Brecht-Krauss D, Heymer B, et al. Fluorodeoxyglucose positron emission tomography of soft tissue tumours: is a non-invasive determination of biological activity possible? Eur J Nucl Med 1999;26:599 - 605.
  380. Schwarzbach M, Willeke F, Dimitrakopoulou-Strauss A, et al. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography. Anticancer Res 1999;19:1343 - 1350.
  381. Schwarzbach MH, Dimitrakopoulou-Strauss A, Willeke F, et al. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas. Ann Surg 2000;231:380 - 386.
  382. Scott WJ, Gobar LS, Terry JD, Dewan NA, Sunderland JJ. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996;111:642 - 648.
  383. Scott WJ, Schwabe JL, Gupta NC, Dewan NA, Reeb SD, Sugimoto JT. Positron emission tomography of lung tumors and mediastinal lymph nodes using (18F)fluorodeoxyglucose. The members of the PET-Lung Tumor Study Group. Ann Thorac Surg 1994;58:698 - 703.
  384. Seltzer MA, Barbaric Z, Belldegrun A, et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J Urol 1999;162:1322 - 1328.
  385. Seltzer MA, Strum SB, Scholz MC, et al. Comparison of whole-body 11C acetate and FDG PET in patients with prostate cancer . J Nucl Med 2000;41:142P.
  386. Seltzer MA, Valk PE, Wong CS, et al. Prospective survey of referring physicians to determine the impact of whole-body FDG-PET on management of cancer patients . J Nucl Med 2000;41:108P.
  387. Shah N, Hoskin P, McMillan A, Gibson P, Lowe J, Wong WL. The impact of FDG positron emission tomography imaging on the management of lymphomas. Br J Radiol 2000;73:482 - 487.
  388. Shankar LK, Yamamoto AJ, Alavi AA, Mandel S. The clinical utility of 18FDG PET in the management of iodine-negative thyroid cancer . J Nucl Med 2000;41:310P.
  389. Shields AF, Ahmed S, Zalupski MM, et al. FDG-PET evaluation of pancreatic cancer treatment . J Nucl Med 1999;40:243P.
  390. Shih YH, Yiu CH, Su MS, et al. Temporal lobectomy in adults with intractable epilepsy. J Formosan Med Assoc 1994;93:307 - 313.
  391. Shreve P, Grossmann H, Gross M, Wahl R. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-(F-18) fluoro-D-glucose. Radiology 1996;199:751 - 756.
  392. Shreve PD, Steventon RS, Deters EC, Kison PV, Gross MD, Wahl RL. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner. Radiology 1998;207:431 - 437.
  393. Shulkin BL, Mitchell DS, Ungar DR, et al. Neoplasms in a pediatric population: 2-(F-18)-fluoro-2-deoxy-D-glucose PET studies. Radiology 1995;194:495 - 500.
  394. Shulkin BL, Thompson NW, Shapiro B, Francis IR, Sisson JC. Pheochromocytomas: imaging with 2-(fluorine-18)fluoro-2-deoxy-D-glucose PET. Radiology 1999;212:35 - 41.
  395. Silverman DH, Chang CY, Cummings JL, et al. Prognostic value of regional brain metabolism in evaluation of dementia: comparison with long-term clinical outcome . J Nucl Med 1999;40:71P.
  396. Silverman DH, Lu CS, Czernin J, Small GW, Phelps ME. Prognostic value of brain PET in patients with early dementia symptoms, treated or untreated with anticholinesterase therapy . J Nucl Med 2000;41:64P.
  397. Silverman DH, Small GW, Kung de Aburto MA, et al. Diagnostic accuracy of FDG-PET in evaluation of dementia: international multi-center pooled brain scan and autopsy data . J Nucl Med 2000;41:63P.
  398. Slosman DO, Spiliopoulos A, Couson F, et al. Satellite PET and lung cancer: a prospective study in surgical patients. Nucl Med Commun 1993;14:955 - 961.
  399. Smith G, Hubner K, McDonald T, Thie J. Avoiding second-look surgery and reducing costs in managing patients with ovarian cancer by applying F-18-FDG PET . Clin Positron Imaging 1998;1:263.
  400. Smith I, Ogston K, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998;228:220 - 227.
  401. Smith IC, Welch A, Chilcott F, et al. 18F-FDG PET may predict the pathological response of breast cancer to primary chemotherapy . J Nucl Med 1999;40:137P.
  402. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676 - 1688.
  403. Snead OC III, Chen LS, Mitchell WG, et al. Usefulness of (18F)fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery. Pediatr Neurol 1996;14:98 - 107.
  404. Spaepen K, Stroobants S, Dupont P, et al. Positron emission tomography with fluorodeoxyglucose after first line chemotherapy in non-Hodgkin´s lymphoma . J Nucl Med 2000;41:70P.
  405. Stefan H, Pawlik G, Böcher-Schwarz HG, et al. Functional and morphological abnormalities in temporal lobe epilepsy: a comparison of interictal and ictal EEG, CT, MRI, SPECT and PET. J Neurol 1987;234:377 - 384.
  406. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997;202:441 - 446.
  407. Steinert HC, Huch Böni RA, Buck A, et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 1995;195:705 - 709.
  408. Steinert HC, Voellmy DR, Trachsel C, et al. Planar coincidence scintigraphy and PET in staging malignant melanoma . J Nucl Med 1998;39:1892 - 1897.
  409. Steinert HC, Von Schulthess GK, Weder W. Effectiveness of whole-body FDG PET imaging in staging of non-small-cell lung cancer (NSCLC) . J Nucl Med 1998;39:80P.
  410. Stokkel M, Stevens H, Taphoorn M, Van Rijk P. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera. A pilot study. Nucl Med Commun 1999;20:411 - 417.
  411. Stokkel MP, de Klerk JH, Zelissen PM, Koppeschaar HP, van Rijk PP. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: preliminary results. Eur J Nucl Med 1999;26:1606 - 1609.
  412. Stokkel MP, Terhaard CH, Hordijk GJ, van Rijk PP. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography. Eur J Nucl Med 1999;26:767 - 773.
  413. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation [see comments]. Radiology 1995;195:339 - 344.
  414. Stumpe K, Urbinelli M, Steinert H, Glanzmann C, Buck A, von Schulthess G. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721 - 728.
  415. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET in patients with cervical cancer. J Nucl Med 1999;40:1125 - 1131.
  416. Sugawara Y, Wald JJ, McGillicuddy JE, Carlson SM, Wahl RL. FDG-PET in evaluation of brachial plexopathy in patients with previously-treated breast cancer . J Nucl Med 1999;40:137P - 138P.
  417. Swartz BE, Halgren E, Delgado-Escueta AV, et al. Neuroimaging in patients with seizures of probable frontal lobe origin. Epilepsia 1989;30:547 - 558.
  418. Szelies B, Grond M, Herholz K, Kessler J, Wullen T, Heiss WD. Quantitative EEG mapping and PET in Alzheimer´s disease. J Neurol Sci 1992;110:46 - 56.
  419. Takeuchi O, Saito N, Koda K, Sarashina H, Nakajima N. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer. Br J Surg 1999;86:932 - 937.
  420. Tamaki N, Kawamoto M, Tadamura E. Prediction of reversible ischemia after revascularization: perfusion and metabolic studies with positron emission tomography. Circulation 1995;91:1697 - 1705.
  421. Tamaki N, Yoshiharu Y, Yamashita K. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860 - 865.
  422. Tanaka F, Yonekura Y, Ikeda A, et al. Presurgical identification of epileptic foci with iodine-123 iomazenil SPET: comparison with brain perfusion SPET and FDG PET. Eur J Nucl Med 1997;24:27 - 34.
  423. Tatsumi M, Tokita N, Nishimura T. Whole-body hybrid positron emission tomography with 18F-FDG in the staging of non-Hodgkin´s lymphoma . J Nucl Med 2000;41:292P.
  424. Tatsumi M, Yutani K, Watanabe Y, et al. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. J Nucl Med 1999;40:566 - 573.
  425. Tedeschi E, Hasselbalch SG, Waldemar G, et al. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 1995;59:608 - 615.
  426. Theodore WH, Dorwart R, Holmes M, Porter RJ, DiChiro G. Neuroimaging in refractory partial seizures: comparison of PET, CT, and MRI. Neurology 1986;36:750. - 759.
  427. Theodore WH, Sato S, Kufta CV, Gaillard WD, Kelley K. FDG-positron emission tomography and invasive EEG: seizure focus detection and surgical outcome. Epilepsia 1997;38:81 - 86.
  428. Thompson TP, Lunsford LD, Kondziolka D. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotactic Funct Neurosurg 1999;73:9 - 14.
  429. Tillisch J, Brunken R, Marshall R. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884 - 888.
  430. Tomas MB, Manalili E, Leonidas JC, Karayalcin G, Lipton J, Palestro CJ. 18F-FDG imaging of lymphoma in children using a hybrid PET system: comparison with 67Ga . J Nucl Med 2000;41:96P.
  431. Torizuka T, Nobezawa S, Nagashima S, et al. Role of whole-body FDG-PET in management of patients with recurrent ovarian cancers . J Nucl Med 2000;41:303P.
  432. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin´s lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET. J Nucl Med 2000;41:999 - 1005.
  433. Trieu TC, Littlefield JL, Lowe VJ, Fletcher JW. The efficacy of FDG-PET in the management of non-small cell lung cancer . J Nucl Med 1997;38:80P.
  434. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol. 1999;94:3314 - 3319.
  435. Turlakow A, Yeung HW, Macapinlac HA, Nunez RF, Sanchez AF, Larson SM. Peritoneal carcinomatosis: the role of FDG-PET . J Nucl Med 2000;41:36P.
  436. Utech C, Young C, Winter P. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996;23:1588 - 1593.
  437. Valk PE, Abella-Columna E, Hasemann MK, et al. Whole-body PET imaging with F-18 fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999;134:503 - 513.
  438. Valk PE, Pounds TR, Hopkins DM, et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg 1995;60:1573 - 1581.
  439. Van Ginkel RJ, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med 1996;37:984 - 990.
  440. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Mediastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer. A prospective analysis of 50 cases. Chest 1997;112:1480 - 1486.
  441. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med 1998;25:1495 - 1501.
  442. Vaylet F, Foehrenbach H, De Dreuille O, et al. Fluorodeoxyglucose and bronchopulmonary cancer. Initial French results with positron emission tomography [in French]. Rev Pneumol Clin 1998;54:187 - 195.
  443. Vitola JV, Delbeke D, Sandler MP, et al. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver. Am J Surg 1996;171:21 - 26.
  444. Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17:1508 - 1515.
  445. Wagner JD, Schauwecker D, Hutchins G, Coleman JJ III. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma. J Surg Oncol 1997;64:181 - 189.
  446. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, Orringer MB. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994;191:371 - 377.
  447. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101 - 2111.
  448. Wang H, Maurea S, Mainolfi C, et al. Tc-99m MIBI imaging in patients with lung cancer: comparison with CT and fluorine-18 FDG PET studies . J Nucl Med 1996;37:260P.
  449. Wang W, Macapinlac H, Larson SM, et al. (18F)-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291 - 2302.
  450. Weber W, Bartenstein P, Gross MW, et al. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors. J Nucl Med 1997;38:802 - 808.
  451. Weber W, Voll B, Treumann T, Watzlowik P, Praeuer H, Schwaiger M. Imaging of lung cancer: comparison of C-11-methionine and F-18-FDG PET . J Nucl Med 1998;39:80P.
  452. Weder W, Schmid RA, Bruchhaus H, Hillinger S, Von Schulthess GK, Steinert HC. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886 - 893.
  453. Whiteford MH, Whiteford HM, Yee LF, et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 2000;43:759 - 770.
  454. Wiedmann E, Baican B, Hertel A, et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin´s disease. Leuk Lymphoma 1999;34:545 - 551.
  455. Wong CS, Valk P, Ariannejad M, et al. Impact of FDG-PET on management of patients with melanoma . J Nucl Med 2000;41:282P.
  456. Wong CYO, Pham AN, Welsh RJ, et al. Supra-CT detection of N3 or M1 lesions of NSC lung cancer by 18F FDG PET . J Nucl Med 2000;41:294P.
  457. Wong WL, Chevretton E, McGurk M, Croft D. PET-FDG imaging in the clinical evaluation of head and neck cancer. J Royal Soc Med 1995;88:469P - 473P.
  458. Wong WL, Chevretton EB, McGurk M, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 1997;22:209 - 214.
  459. Yang WI, Choi CW, Lee YS, et al. Whole body (18F) FDG PET in patients with cervical lymph node metastases of unknown primary site . J Nucl Med 1999;40:259P - 260P.
  460. Yap CS, Valk P, Ariannejad M, et al. FDG-PET influences the clinical management of lymphoma patients . J Nucl Med 2000;41:70P.
  461. Yap CS, Valk P, Ariannejad M, et al. Evaluation of FDG-PET for the clinical management of breast cancer patients . J Nucl Med 2000;41:109P.
  462. Yasuda S, Makuuchi Y, Sadahiro S, et al. Colorectal cancer recurrence in the liver: detection by PET. Tokai J Exp Clin Med 1998;23:167 - 171.
  463. Yeh SDJ, Imbriaco M, Garza D, et al. Twenty percent of bony metastases of hormone-resistant prostate cancer are detected by PET-FDG whole body scanning . J Nucl Med 1995;36:198P.
  464. Yeung H, Macapinlac H, Mazumdar M, Bains M, Finn R, Larson S. FDG-PET in esophageal cancer: incremental value over computed tomography. Clin Positron Imaging 1999;2:255 - 260.
  465. Yutani K, Hojo S, Tatsumi M, Shiba E, Noguchi S, Nishimura T. Correlation of F-18-FDG and Tc-99m-MIBI uptake with proliferative activity in breast cancer . J Nucl Med 1999;40:16P - 17P.
  466. Yutani K, Shiba E, Kusuoka H, et al. Comparison of FDG-PET with MIBI-SPECT in the detection of breast cancer and axillary lymph node metastasis. J Comput Assist Tomogr 2000;24:274 - 280.
  467. Yutani K, Tatsumi M, Uehara T, Nishimura T. Effect of patients´ being prone during FDG PET for the diagnosis of breast cancer. AJR. 1999;173:1337 - 1339.
  468. Yutani K, Uehara T, Nishimura T. Detectability of FDG-PET and MIBI-SPECT to breast tumor . J Nucl Med 1997;38:68P.
  469. Zeitouni AG, Yamamoto YL, Black M, Gjedde A. Functional imaging of head and neck tumours using positron emission tomography. J Otolaryngol 1994;23:77 - 80.
  470. Zhuang HM, Sinha P, Pourdehnad M, Duarte PS, Alavi AA. The crucial role of FDG-PET in the evaluation of liver metastasis from colorectal cancer . J Nucl Med 2000;41:35P.
  471. Zimny M, Bares R, Frass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997;24:678 - 682.
  472. Zimny M, Nowak B, Di Martino E, Jaenicke S, Cremerius U, Buell U. Hybrid PET vs. conventional imaging in the diagnosis of head and neck tumors . J Nucl Med 2000;41:292P.
  473. Zimny M, Schröder W, Wolters S, Cremerisu U, Rath W, Büll U. 18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results [in German]. Nuklearmedizin 1997;36:228 - 233.
  474. Zinzani P, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181 - 1184.


    475. Back to top.


    Previous: Appendix C: Abbreviations Legend

    MI LifeNet | Privacy | © 2012